Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study.


3531 Background: Bevacizumab (B) in combination with chemotherapy prolongs progression-free survival (PFS) in patients with mCRC. However, the subgroup that derives greatest benefit with B is not known. Since B only targets VEGF A and given the redundancy within biologic family members, we hypothesized that overexpression of other VEGF ligands could… (More)